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Abstract
Background:  Insulin-like growth factor binding protein 5 (IGFBP5) has been shown to be
associated with breast cancer metastasis in clinical marker studies. However, a major difficulty in
understanding how IGFBP5 functions in this capacity is the paradoxical observation that ectopic
overexpression of IGFBP5 in breast cancer cell lines results in suppressed cellular proliferation. In
cancer tissues, IGFBP5 resides mainly in the cytoplasm; however, in transfected cells, IGFBP5 is
mainly located in the nucleus. We hypothesized that subcellular localization of IGFBP5 affects its
functions in host cells.
Methods:  To test this hypothesis, we generated wild-type and mutant IGFBP5 expression
constructs. The mutation occurs within the nuclear localization sequence (NLS) of the protein and
is generated by site-directed mutagenesis using the wild-type IGFBP5 expression construct as a
template. Next, we transfected each expression construct into MDA-MB-435 breast cancer cells
to establish stable clones overexpressing either wild-type or mutant IGFBP5.
Results: Functional analysis revealed that cells overexpressing wild-type IGFBP5 had significantly
lower cell growth rate and motility than the vector-transfected cells, whereas cells overexpressing
mutant IGFBP5 demonstrated a significantly higher ability to proliferate and migrate. To illustrate
the subcellular localization of the proteins, we generated wild-type and mutant IGFBP5-pDsRed
fluorescence fusion constructs. Fluorescence microscopy imaging revealed that mutation of the
NLS in IGFBP5 switched the accumulation of IGFBP5 from the nucleus to the cytoplasm of the
protein.
Conclusion: Together, these findings imply that the mutant form of IGFBP5 increases proliferation
and motility of breast cancer cells and that mutation of the NLS in IGFBP5 results in localization of
IGFBP5 in the cytoplasm, suggesting that subcellular localization of IGFBP5 affects its cell growth
and migration functions in the breast cancer cells.
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Background
Insulin-like growth factor (IGF) binding protein-5
(IGFBP5) is the most evolutionarily conserved member in
a family of 6 high-affinity IGF-binding proteins [1,2].
IGFBP5 has been shown to have a potential role in car-
cinogenesis that involves 2 main pathways [3,4]. One is
the IGF-dependent pathway. The other is the IGF-inde-
pendent pathway, which is more complicated and less
understood than the IGF-dependent pathway. Recently,
Duan and colleagues showed that IGFBP5 promotes cell
differentiation by regulating IGF-II actions [5]. Many of
the recently published studies of IGFBP5 have focused on
the involvement of the protein in apoptosis, protein-pro-
tein interaction, cell motility, cell survival, and cellular
trafficking [6]. C-terminal domain of IGFBP5 contains a
region known as the nuclear localization sequence (NLS;
at amino acids 201 to 218)) [7,8] that is responsible for
the nuclear transport of IGFBP5. The NLS contains a
heparin-binding motif (HBM, consensus sequence
BBBXXB, where B is a basic amino acid and X is any amino
acid) at amino acids 206 to 211 (KRKQCK) and carries
alternative IGF-binding sites [9,10]. Therefore, this region
seems to be critical in determining the diverse functions of
IGFBP5. It has been shown that IGFBP5 stimulates cell
migration through interaction with cell surface heparan
sulfate proteoglycans [11] and this activity is negatively
regulated by fibronectin [12]. IGFBP5 has been shown to
determine cell fates by regulating apoptotic molecules
(bax, bcl-2) [13] and activating p38 MAP kinase and Erk
1/2 signal transduction pathways [14]. Reports also show
that IGFBP5 regulates gene transcriptions [15]. Thus,
IGFBP5 has diverse functions in different cellular com-
partment.
Using cDNA and tissue microarray technologies, we and
others have found that IGFBP5 overexpression is associ-
ated with a poor prognosis and with metastasis in patients
with breast cancer [16-19]; however, the mechanism by
which IGFBP5 promotes metastasis is unknown. Results
from gain-of-function studies conducted via forced
expression of IGFBP5 in breast cancer cell lines has shown
a surprising inhibitory effect of IGFBP5 on cell prolifera-
tion [13,20]. In these in vitro studies, IGFBP5 was found to
be localized to the nucleus [7,8]. In contrast, immunohis-
tochemistry studies of breast cancer tissues have shown
IGFBP5 to be localized mainly to the cytoplasm [18,19].
These findings suggest that the cellular localization of
IGFBP5 determines whether it has a stimulatory or inhib-
itory effect on cells.
To test our hypothesis that subcellular localization of
IGFBP5 affects its functions in host cells, we generated a
construct containing a deleted form of IGFBP5 in which
the last 5 amino acids in the NLS were deleted. Next, we
established cell lines overexpressing either the wild-type
or the mutant form of IGFBP5 using MDA-MB-435 as the
parental cell line and investigated the effects of the wild-
type and mutant proteins on cell proliferation and motil-
ity. To visualize the subcellular localization of IGFBP5, we
generated IGFBP5-pDsRed fluorescence fusion constructs
containing either wild-type or mutant IGFBP5. Deletion
of the last 5 amino acids of NLS in IGFBP5 eliminated
nuclear localization of IGFBP5 and significantly promotes
breast cancer cell proliferation and motility.
Methods
Plasmid construction
The full-length IGFBP5 cDNA was generated by reverse
transcriptase-polymerase chain reaction (RT-PCR) using
total RNA from MCF7 breast cancer cell line. The primer
sequence was: forward primer, 5'-GCCACCATGGTGTT-
GCTCACCGCGGTCCTCCTGC-3'; and reverse primer, 5'-
TCACTCAA-CGTTGCTGCTGTCGAAGGTGTG-3'. A
Kozak consensus GCCACC is inserted in front of the
IGFBP5 translation initiation site to increase the transla-
tion efficiency. The PCR product was inserted into
pCR®2.1TOPO plasmid (Invitrogen, Carlsbad, CA), and
several clones were chosen for DNA sequencing. The
IGFBP5 cDNA with the wild-type sequence was digested
from the TA-cloning plasmid using EcoRI restriction
enzyme and was inserted into the EcoRI site of the
pcDNA3.1(+) expression vector (Invitrogen) to obtain the
IGFBP5wt/pcDNA3.1(+) construct. Again, several clones
were sequenced, and the clone with right orientation and
the cDNA sequence was chosen to perform cell transfec-
tion to generate wild-type IGFBP5-overexpressing cell
lines. The mutant IGFBP5 expression construct
[IGFBP5mt/pcDNA3(+)] was generated using the Quick-
Change Kit (Stratagene, La Jolla, CA) using the IGFBP5wt/
pcDNA3.1(+) expression plasmid as a template. As shown
in Figure 1A, 5 amino acids in the NLS (214 to 218; black
characters) were deleted. Several clones were sequenced,
and the clone with right orientation and IGFBP5 cDNA
with the mutant sequence was chosen to perform the
transfection and to generate mutant IGFBP5-overexpress-
ing cell lines.
To generate wild-type and mutant IGFBP5 fluorescence
fusion proteins, we used the same upstream primer used
to generate the wild-type IGFBP5 expression construct. To
make the fusion protein in the reading frame, a new
downstream primer was generated using the following
sequence: 5'-CCGGAATTCCGGACTCAACGTTGCTGCT-
GTCGAAGG-TGTG-3'. The PCR products were generated
using the IGFBP5wt/pcDNA3.1(+) and the IGFBP5mt/
pcDNA3.1(+) plasmids to generate wild-type and mutant
IGFBP5-fluorecence fusion proteins (respectively). The
PCR products were inserted into the pDsRed2-N1 vector
(BD Biosciences, San Jose, CA) at the EcoRI restriction
enzyme site after digestion with the same enzyme toBMC Cancer 2009, 9:103 http://www.biomedcentral.com/1471-2407/9/103
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obtain the IGFBP5wt/pDsRed2-N1 and the IGFBP5mt/
pDsRed2-N1 constructs.
Generation of stably transfected cell lines
MDA-MB-435 cells were grown at 70% confluence and
transfected with the pcDNA3.1(+) vector alone, with
IGFBP5wt/pcDNA3.1(+), and with IGFBP5mt/
pcDNA3.1(+) using Nucleofector (Amaxa, Gaithersburg,
MD). The transfection was performed with Solution T and
program T20. Selection of stable cell clones was carried out
in the presence of 600 μg/ml G418 (Invitrogen) in culture
medium at 48 h post-transfection, and the cells were re-
fed every 3 days. Several single clones were selected and
expanded for 2–3 weeks, and the IGFBP5 expression level
was detected by western blot analysis.
Analysis of BrdU incorporation
The cell growth rates of the vector and of the wild-type and
the mutant IGFBP5 transfectants were measured by bro-
modeoxyuridine (BrdU) incorporation using BrdU flow
kits (BD Biosciences) per the manufacturer's instructions.
Briefly, the cells were cultured in complete medium for 24
h and then incubated in fresh complete medium with 10
μM BrdU for 2 h. The incorporated BrdU was visualized
by immunofluorescence staining using an anti-BrdU anti-
body conjugated with fluorescein isothiocyanate. The
nuclei were counterstained with DAPI, and images were
taken at a magnification of 63×. Cells not treated with
anti-BrdU antibody served as negative controls. The
number of total cells and the BrdU-positive cells were
counted from 3 fields of each group under a fluorescence
Establishment of the wild-type and mutant forms of IGFBP5 stably expressing cell lines Figure 1
Establishment of the wild-type and mutant forms of IGFBP5 stably expressing cell lines. A. Schematic diagram of 
the IGFBP5 cDNA fragments used to generate the IGFBP5 expression constructs. Wild-type IGFBP5 contains a NLS located at 
the C-terminal domain of the protein from amino acid 201 to 218 and indicated by a gray solid square. For the mutant form of 
IGFBP5, 5 amino acids in the NLS from 214–218 (black characters) were deleted. B. Western blot analysis of IGFBP5 expres-
sion. MBA-MD-435 breast cancer cells were stably transfected with either the wild-type or the mutant forms of IGFBP5 con-
struct and the whole cell lysate from parental MBA-435 cells (P) and different stable lines were subjected to western blot 
analysis (40 μg/lane) using an anti-human IGFBP5 antibody. The blot was re-probed with actin to normalize for protein loading. 
Neither parental nor vector-transfectant (V) cells had detectable levels of IGFBP5. 10 ng of purchased human recombinant 
IGFBP5 protein was served as a positive control (+). wt, wild-type and d, deletion form IGFBP5.
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microscope, and the quantification data were graphed as
a ratio of the number of BrdU-positive cells to the number
of total cells. The geometric mean fluorescence intensity
from the same cell population was recorded by fluores-
cence-activity cell sorter (FACS) analysis. The fluorescence
intensity from the negative control was graphed as zero,
and the fluorescence intensity from the rest of the samples
became the value remaining after the fluorescence inten-
sity was subtracted from the negative control.
Cell culture and fluorescence microscopy imaging
The MDA-MB-435 breast cancer cell line was obtained
from the American Type Culture Company (ATCC;
Menassas, VA) and was routinely maintained in Dul-
becco's modified Eagle's medium/F-12 supplemented
with 10% fetal bovine serum (FBS) and 1% antibiotic
cocktail under standard conditions. For microscopy imag-
ing, 2 × 104  IGFBP5wt/pDsRed2-N1 or IGFBP5mt/
pDsRed2-N1 fusion construct-transfected cells were
seeded per cell into glass slide chambers (BD Pharmin-
gen) and allowed to attach for 40 h. The cells were then
fixed with 4% paraformaldehyde in phosphate-buffered
saline. After washing, the cells were counterstained with
DAPI. Images were taken using an Axioplan 2 fluores-
cence microscope (ZEISS, Oberkochen, Germany) at 63×
magnification.
In vitro migration assay
Falcon cell-culture inserts containing an 8-μ pore PET
membrane (BD Biosciences) were used to perform the in
vitro migration assay. The vector-alone transfectants and
the IGFBP5wt/pcDNA3.1(+) and IGFBP5mt/
pcDNA3.1(+) stable cells were seeded into the upper
chambers at a density of 2 × 104 cells/well in 500 μl of
serum-free medium. To the lower chambers, 1 ml of 10%
FBS-containing medium was added. The plates were then
incubated for 20 h at 37°C with 5% CO2. The unmigrated
cells in the upper chambers were gently removed using a
cotton swab. Cells that had migrated through the mem-
brane pore into the lower sides of the filters were fixed,
stained with HEMA-DIFF solution (Fisher Scientific, Phil-
adelphia, PA), and counted under a regular light micro-
scope.
Western blot analysis
IGFBP5 in the whole-cell lysate and conditioned media
(CM) was detected according to a previously describe
standard protocol [21]. Briefly, cell lysates from different
cell populations were collected, and protein concentra-
tion was measured using the Bio-Rad protein assay (Bio-
Rad Laboratories, Hercules, CA). Equal amounts of pro-
teins were then loaded into 10% sodium dodecyl sulfate-
polyacrylimide gels and resolved by electrophoresis. After
transfer to nitrocellulose membranes, it was probed with
anti-IGFBP5 antibody (diluted 1:1000 in TBST, 5% non-
fat dry milk; Santa Cruz Biotechnology, Santa Cruz, CA).
Bands were detected using the chemiluminescence detec-
tion method (Amersham Biosciences, Piscataway, NJ) and
exposed on x-ray film. The IGFBP5 level in the same vol-
ume of conditioned media from the same cell popula-
tions of similar densities for the cell lysate was measured
simultaneously.
Statistical analysis
Data are expressed as the mean ± standard error. Statistical
analysis was performed using the Student's t test. Differ-
ences in means were evaluated by a 2-tailed t test assum-
ing unequal variances. A p value of ≤ 0.05 was considered
statistically significant.
Results
Deletion of amino acids 214 to 218 of IGFBP5 altered 
subcellular localization of the protein in the MDA-MB-435 
breast cancer cells
To determine whether the nuclear localization sequence is
required and sufficient for transporting IGFBP5 into the
nucleus, we constructed a mutant IGFBP5 expression vector
in which 5 amino acids in the NLS were deleted (Figure
1A). We transfected both wild-type and mutant IGFBP5
expression vectors into the MDA-MB-435 breast cancer
cells, and established several stable cell lines overexpressing
these vectors. IGFBP5 expression was detected in the cells
by western blot analysis using whole-cell lysates (Figure
1B). The parental cells and the vector-alone transfectants
were used as controls. In order to visualize the subcellular
localization of wild-type and mutant IGFBP5 in the cells,
we generated constructs that fused fluorescent pDesRed on
the C-terminal region of either wild-type IGFBP5 or mutant
IGFBP5. After transfection of the expressing vectors, we
observed that wild-type IGFBP5 was mostly localized in the
nucleolus. The nucleolus localization of wild-type IGFBP5
was confirmed by the observation of colocalization of
IGFBP5 and the known nucleolus protein B23 [22] (Figure
2). Mutated IGFBP5 was not detected in the nucleolus but
was detected at a low level in the cytoplasm (Figure 3). To
determine whether the low cytoplasmic level of mutant
IGFBP5 was the result of increased secretion of the IGFBP5
into the media, we collected both cell lysate and condi-
tional media from the stable cell lines and performed west-
ern blot analysis. Again, we could not detect IGFBP5 from
either the cell lysates or the conditioned media in the
parental and vector-transfected cells (Figure 4). We did
observe overexpression of IGFBP5 from the IGFBP5wt and
IGFBP5mt stable clones, and the cells overexpressing the
mutant form IGFBP5 showed a much higher level of
IGFBP5 in the conditioned medium compared with the
wild-type IGFBP5 transfectants (Figure 4). Interestingly, we
observed that the majority of the secreted wild-type IGFBP5
was cleaved whereas that majority of the mutant IGFBP5
remained intact in the conditioned media (Figure 4).BMC Cancer 2009, 9:103 http://www.biomedcentral.com/1471-2407/9/103
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Deletion of amino acids 214 to 218 of IGFBP5 protein 
promoted proliferation of MDA-MB-435 breast cancer 
cells
To determine any proliferative effects of the mutant form
of IGFBP5, we performed BrdU incorporation analyses by
flow cytometry and fluorescence microscopy. The cells
overexpressing wild-type or mutant IGFBP5 were cultured
in the complete media for 24 h and then incubated in the
fresh complete media with 10 μM of BrdU for 2 h. The
vector alone transfectant was used as the control. The
incorporated BrdU was visualized by immunofluores-
cence staining using an anti-BrdU antibody conjugated
with fluorescein isothiocyanate. Cells with no anti-BrdU
antibody treatment served as the negative controls for the
immunostaining. More cells overexpressing the mutant
form of IGFBP5 were positively stained compared with
the vector and the wild-type IGFBP5-overexpressing cells
(Figure 5A). To obtain quantification data from the assay,
we randomly chose 3 fields to count the total cells and the
BrdU positive cells, and the data were graphed as a ratio of
BrdU positive cells to total cells. The result revealed that
overexpression of wild-type IGFBP5 significantly inhib-
ited BrdU incorporation compared with the vector trans-
fectants (*, p < 0.05) (Figure 5B). In contrast,
overexpression of the mutant IGFBP5 significantly pro-
moted BrdU incorporation (**, p < 0.005) (Figure 5B). To
confirm our findings, the geometric mean fluorescence
intensity from the same cell populations after the immun-
ofluorescence staining was recorded by FACS. The fluores-
cence intensity from the negative control was graphed as
zero, and fluorescence intensity from the rest of samples
was the value after the fluorescence intensity value was
subtracted from the negative control. The results from
FACS analysis showed that wild-type IGFBP5 inhibited
cell growth compared with the vector transfectant and that
the mutated form of IGFBP5 promoted cell growth com-
pared with the vector transfectant (Figure 5C and 5D).
Deletion of amino acids 214 to 218 of IGFBP5 enhanced 
breast cancer cell motility
To determine whether mutation of NLS of IGFBP5 affects
cell motility, we performed an in vitro migration assay using
the stable cells overexpressing either wild-type or mutant
IGFBP5. The vector-alone transfected cells were used as the
control. As shown in Figure 6, the mutant IGFBP5-overex-
pressing cells had a significantly higher number of migrated
cells than the vector-alone control cells (p < 0.01) (Figure
6A and 6B). In contrast, the wild-type IGFBP5-overexpress-
ing cells had significantly lower numbers of migrated cells
than the vector-alone control cells (p < 0.001) (Figure 6A
Deletion of amino acids from 214 to 218 of IGFBP5 protein  eliminates its nuclear localization Figure 2
Deletion of amino acids from 214 to 218 of IGFBP5 
protein eliminates its nuclear localization. The wild-
type (IGFBP5wt/pDsRed2-N1) or mutant (IGFBP5mt/
pDsRed2-N1) fusion construct was transiently transfected 
into MBA-MD-435 breast cancer cells. The cells were fixed 
48 h post-transfection and counterstained with DAPI. The 
images were taken by a fluorescence microscope at 63× 
magnification.
DAPI              IGFBP5wt/pDsRed             Merge
DAPI             IGFBP5mt/pDsRed              Merge
Wild-type IGFBP5 mainly localized at the cellular nucleolus Figure 3
Wild-type IGFBP5 mainly localized at the cellular nucleolus. IGFBP5 wt/pDsRed2-N1 and B23/pGFP constructs were 
co-transfected into MBA-MD-435 cells. After 48 h post-transfection, the cells were fixed and counterstained with DAPI. The 
IGFBP5 fusion protein showed co-localization with B23, which is a marker for the nucleolus.
DAPI                 IGFBP5(wt)/pDsRed             B23/pGFP      MergeBMC Cancer 2009, 9:103 http://www.biomedcentral.com/1471-2407/9/103
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and 6B). To confirm that deletion of amino acids 214 to
218 within the NLS of IGFBP5 promotes breast cancer cell
motility, we transiently transfected the MDA-MB-435
breast cancer cells with IGFBP5wt/pcDNA3.1(+) and
IGFBP5mt/pcDNA3.1(+) constructs and performed the in
vitro  migration assay 48-h post-transfection. The vector-
alone transfected cells were used as the control. As shown
in Figure 6C, we observed results similar to those from the
in vitro migration experiments carried out using the stable
cells. IGFBP5wt/pcDNA3.1(+)-transfected cells had a sig-
nificantly lower number of migrated cells than the vector-
alone control cells (* p < 0.05). In contrast, IGFBP5mt/
pcDNA3.1(+)-transfected cells had a significantly higher
number of migrated cells than the control cells (** p <
0.001) (Figure 6C).
Discussion
There are contradictory findings and implications regard-
ing whether IGFBP5 has enhancing and inhibitory effects
on cells in breast cancer [6,13,20,23,24]. Clinical observa-
tions show that IGFBP5 is associated with the metastatic
tumor phenotype in breast cancer, thus IGFBP5 is a poor
prognostic factor and may serve as a target for therapeutic
development [18,19,25,26]. The matter becomes compli-
cated when attempting to understand the function of
IGFBP5 in cell culture assays in vitro, studies have shown
that IGFBP5 induces breast cancer cell apoptosis [13,20].
In this study, we provide evidence that the cellular locali-
zation of IGFBP5 is a key factor that affects its function in
the cells. In primary cancer cells in tumor tissues, IGFBP5
is mainly located in the cytoplasm, whereas in cell culture,
exogenously introduced IGFBP5 is mainly localized in the
nucleus using its nuclear localization signal. When we
deleted this signal from the IGFBP5, the function of
IGFBP5 is switched from a growth inhibitory one to a
growth and migration stimulating one, which is consist-
ent with clinical observation that cytoplasmic IGFBP5 as a
poor prognostic factor.
Recently, Jurgeit and colleagues also analyzed cytoplasmic
trafficking and cellular localization of IGFBP5 in T47D
breast cancer cell line and in paraffin sections of involut-
ing mammary glands [27]. They examined the secretion
and re-uptake of IGFBP5 of different mutant forms of the
protein that either deleted signal peptide or NLS. They
reported that that cellular localization of IGFBP5 was
affected by secretion. They observed that the endogenous
IGFBP5 was secreted into extracellular compartment via
intracellular vesicles, taken up by cells, and then trans-
ported to vesicular compartments outside the nucleus.
They suggested that wild-type IGFBP5 could not be local-
ized in the nucleus under in vivo conditions and nuclear
location of IGFBP5 was dependent on NLS. Jurgeit's find-
ings in principle agree with our findings that IGFBP5
change cellular localization under different conditions
although these conditions are yet to be clearly identified.
Our studies have some different results, which resulted
from different mutations in the NLS. We deleted the 214–
218 (RGRKR) amino acids in NLS of IGFBP5, whereas Jur-
geit and colleagues changed amino acids from RGRKR to
LNGQL. It is not clear why the two different types of alter-
ation generated some different phenotypes, but it is clear
the NLS localization is critical for IGFBP5 function and
our study showed that prevention of nuclear localization
of IGFBP5 altered its function in the cells in a fashion that
is consistent with in vivo clinical observation of IGFBP5.
Western blot analysis of IGFBP5 expression in both cell lysate and conditioned medium Figure 4
Western blot analysis of IGFBP5 expression in both cell lysate and conditioned medium. One million cells were 
cultured in 100-mm diameter tissue culture dish in the complete medium for 24 h followed by an additional 24-h incubation in 
the serum-free medium. Both cell lysate and conditioned medium were collected. The conditioned medium was concentrated 
3 times using YM-10 column (Millipore) and 40 μg of protein from the cell lysate and 45 μl of the concentrated conditioned 
medium were subject for western blot analysis. The blot was re-probed with anti-actin to normalize for protein loading. wt, 
wild-type and mt, mutant form IGFBP5.
Possible fragmented 
bands of IGFBP5
P             V            wt            mtBMC Cancer 2009, 9:103 http://www.biomedcentral.com/1471-2407/9/103
Page 7 of 10
(page number not for citation purposes)
However, deletion of the nuclear localization signal (NLS)
from IGFBP5 does not occur in vivo. Thus, the studies
using the deletion mutants represent a somewhat artificial
condition although it is suggestive of potential mecha-
nisms. Thus, a yet-to-be identified mechanism causing
cytoplasmic localization of IGFBP5 operates in breast can-
cer tissues. It is conceivable that IGFBP5 in breast cancer
tissues binds to another protein that modifies its confor-
mation and deletion of the NLS has a similar effect on the
conformation, which may prove to be important for
IGFBP5 localization and function.
There is a precedent in p53 tumor suppressor protein for
such a mechanism to operate in breast cancer. The tumor
suppressor protein p53 is normally localized in the
nucleus, where it functions as a transcriptional factor for
Changes of IGFBP5 cellular distribution promotes breast cancer cell proliferation Figure 5
Changes of IGFBP5 cellular distribution promotes breast cancer cell proliferation. The cell growth rates for the 
vector and IGFBP5 transfectants were measured by BrdU incorporation using the BrdU flow kits per the manufacturer's 
instruction. A. The cells were incubated in 10% FBS medium containing 10 μM BrdU for 2 h followed by immunofluorescence 
staining with FITC conjugated BrdU antibody. The nuclei were counterstained with DAPI and images were taken at a magnifi-
cation of 63×. Non-BrdU-treated parental cells were served as a negative control. B. Quantification data from 3 fields of each 
group. The total cells and the BrdU-positive cells were counted from 3 fields of each group, and the data were graphed as a 
ratio of BrdU positive cells vs. the total cells. The error bars represents standard deviation from three counts of samples. *, p 
< 0.05 and **, p < 0.005.C. The geometric mean fluorescence intensity from the same cell population as in A was recorded by 
FACS. D. The fluorescence intensity shown in B is shown as a bar graph. The fluorescence intensity from the negative control 
is graphed as zero, and the fluorescence intensity from the rest of the samples is the value after the value of the fluorescence 
intensity is subtracted from the negative control.
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genes involved in cell growth inhibition and apoptosis
induction. Inactivation of the p53 tumor suppressor gene
as the result of a mutation is one of the most recognized
changes in cancer, with about 50% of cancers having such
a mutation. Although mutated p53 is present in the
nucleus, the mutations render it unable to bind to DNA
and activate gene transcription [28]. In the other 50% of
tumors, p53 is present and has a wild-type sequence.
However, in these cases, the p53 pathway is inactivated
through other means. One means is through the subcellu-
lar localization of the protein. p53 was first found in the
cytoplasm in many inflammatory breast cancers [29] and
then later in other tumors such as neuroblastomas [30].
The cytoplasmic localization of this wild-type p53 has
now been associated with resistance to chemotherapy and
radiation therapy and with a poor prognosis [31,32]. It
was proposed that various proteins, including ribosomal
proteins, vimentin, and tubulin, were involved in the
abnormal localization of p53 in the cytoplasm [33-35].
Recently, an anchoring protein called Parc, or p53-associ-
ated parkin-like cytoplasmic protein [36], was found to
bind p53 at the nuclear localization domains of p53 and
attenuates the function of p53. The inactivation of endog-
enous Parc by siRNA was observed to restore the nuclear
localization of p53 and sensitized the cells to DNA dam-
age-induced cell death [37].
In our next investigation, we will determine whether Parc
is the key regulator that renders IGFBP5 cytoplasmic in
breast cancer cells in tumors and contributes to the
growth and migration stimulatory effect. If Parc turns out
not to be the regulator, identification of a new IGFBP5
regulator in the cells will certainly opens a new window
into the pathogenesis of breast cancer biology. Interest-
ingly, a recent report [38] suggests that IGFBP-5 regulates
vascular cellular senescence via a p53-dependent
Deletion of 5 amino acids from 214 to 218 of IGFBP5 protein promotes MDA-MB-435 breast cancer cell motility Figure 6
Deletion of 5 amino acids from 214 to 218 of IGFBP5 protein promotes MDA-MB-435 breast cancer cell motil-
ity. A. Representative light-microscopy images from the migration assay. B. Quantification data of in vitro migration assay from 
vector transfectants (vector 1 and vector 4), wild-type IGFBP5 overexpression clones (wt-c11 and wt-c13), and mutant 
IGFBP5 overexpression clones (mt-c2, mt-c6, and mt-c29). The error bars represent standard deviations from 2 separate 
experiments with triplicate samples for each (n = 6). *, p < 0.001. C. Quantification data of in vitro migration assay from tran-
sient transfection. The error bars represent standard deviations from triplicate samples. *, p < 0.05 and **, p < 0.001.
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pathway, thus the link between p53 and IGFBP5 may turn
out to be closer than currently understood.
Conclusion
The present study showed that deletion of 5 amino acids
(214 to 218, RGRKR) within the NLS of IGFBP5 resulted
in change in subcellular location of IGFBP5 and increased
proliferation and motility of MDA-MB-435 breast cancer
cells. This study provides supporting evidence that cellular
localization of IGFBP5 is important for its functions in
breast cancer.
Abbreviations
IGFBP5: insulin-like growth factor binding protein-5; IGF:
insulin-like growth factor; NLS: nuclear localization
sequence; HBM: heparin-binding motif; BrdU: bromode-
oxyuridine; FACS: fluorescence-activity cell sorter; FITC:
fluorescein isothiocyanate.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
Both MA and LH performed the experimental studies and
the statistical analysis, and they participated equally in
drafting the manuscript. AS and XH contributed to the
design of the study and interpretation of results; WZ con-
ceived the study, contributed to the design of the study
and interpretation of results, and worked on the manu-
script. All authors read and approved the final manu-
script.
Acknowledgements
We thank Hong Zheng for her technical assistance. We thank Dr. Mark 
Olson for providing us with the B23/GFP plasmid. We would also like to 
thank Vickie J. Williams in the Department of Scientific Publication of M. D. 
Anderson Cancer Center for editorial assistance. This work was partly sup-
ported by a grant (BC044966 to WZ) from the Department of Defense 
Breast Cancer Research Program of the Office of the Congressionally 
Directed Medical Research Programs and a grant (SBAG-107S099 to MA) 
from the Scientific and Technological Research Council of Turkey 
(TUBITAK).
References
1. Allander SV, Larsson C, Ehrenborg E, Suwanichkul A, Weber G, Mor-
ris SL, et al.: Characterization of the chromosomal gene and
promoter for human insulin-like growth factor binding pro-
tein-5.  J Biol Chem 1994, 269:10891-10898.
2. Firth SM, Baxter RC: Cellular actions of the insulin-like growth
factor binding proteins.  Endocrine Reviews 2002, 23:824-854.
3. Mohan S, Baylink DJ: IGF-binding proteins are multifunctional
and act via IGF-dependent and -independent mechanisms.  J
Endocrinol 2002, 175:19-31.
4. Beattie J, Allan GJ, Lochrie JD, Flint D: Insulin-like growth factor-
binding protein-5 (IGFBP5): a critical member of the IGF
axis.  Biochem J 2006, 395:1-19.
5. Ren H, Yin P, Duan C: IGFBP-5 regulates muscle cell differen-
tiation by binding to IGF-II and switching on the IGF-II auto-
regulation loop.  J Cell Biol 2008, 182:979-991.
6. Akkiprik M, Feng Y, Wang H, Chen K, Hu L, Sahin A, Krishnamurthy
S, Ozer A, Hao X, Zhang W: Multifunctional roles of Insulin-like
growth factor binding protein 5 in breast cancer.  Breast Can
Res 2008, 10:212.
7. Schedlich LJ, Young TF, Firth SM, Baxter RC: Insulin-like Growth
Factor-binding Protein (IGFBP)-3 and IGFBP5 Share a Com-
mon Nuclear Transport Pathway in T47D Human Breast
Carcinoma Cells.  J Biol Chem 1998, 273:18347-18352.
8. Schedlich LJ, Page LL, Firth SM, Briggs LJ, Jans DA, Baxter RC:
Nuclear import of igfbp-3 and -5 is mediated by the importin
beta subunit.  J Biol Chem 2000, 275:23462-23470.
9. Abrass CK, Berfield AK, Andress DL: Heparin binding domain of
insulin-like growth factor binding protein-5 stimulates
mesangial cell migration.  Am J Physiol 1997, 273:F899-906.
10. Allan GJ, Tonner E, Szymanowska M, Shand JH, Kelly SH, Phillips K,
Clegg RA, Gow IF, Beattie J, Flint DJ: Cumulative mutagenesis of
the basic residues in the 201–218 region of IGF-binding pro-
tein-5 results in progressive loss of both IGF-I binding and
inhibition of IGF-I biological action.  Endocrin 2006,
147:338-349.
11. Hsieh T, Gordon RE, Clemmons DR, Busby WH Jr, Duan C: Regu-
lation of vascular smooth muscle cell responses to insulin-
like growth factor (IGF)-I by local IGF-binding proteins.  J Biol
Chem 2003, 278:42886-42892.
12. Xu Q, Yan B, Li S, Duan C: Fibronectin binds insulin-like growth
factor-binding protein 5 and abolishes Its ligand-dependent
action on cell migration.  J Biol Chem 2004, 279:4269-4277.
13. Butt AJ, Dickson KA, McDougall F, Baxter RC: Insulin-like growth
factor binding protein-5 inhibits the growth of human breast
cancer cells in vitro and in vivo.  J Biol Chem 2003,
278:29676-29685.
14. Kuemmerle JF, Zhou H: Insulin-like growth factor-binding pro-
tein-5 (IGFBP-5) stimulates growth and IGF-I secretion in
human intestinal smooth muscle by Ras-dependent activa-
tion of p38 MAP kinase and Erk1/2 pathways.  J Biol Chem 2002,
277:20563-20571.
15. Xu Q, Li S, Zhao Y, Maures TJ, Yin P, Duan C: Evidence that IGF
binding protein-5 functions as a ligand-independent tran-
scriptional regulator in vascular smooth muscle cells.  Circ Res
2004, 94:E46-54.
16. Hao X, Sun B, Hu L, Lahdesmaki H, Dunmire V, Feng Y, Zhang SW,
Wang H, Wu C, Wang H, Fuller GN, Symmans WF, Shmulevich I,
Zhang W: Differential gene and protein expression in primary
breast malignancies and their lymph node metastases as
revealed by combined cDNA microarray and tissue microar-
ray analysis.  Cancer 2004, 100:1110-1122.
17. Van 't Veer LJ, Dai H, Vijver MJ van de, He YD, Hart AA, Mao M,
Peterse HL, Kooy K van der, Marton MJ, Witteveen AT, Schreiber GJ,
Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene
expression profiling predicts clinical outcome of breast can-
cer.  Nature 2002, 415:530-536.
18. Li X, Cao X, Li X, Zhang W, Feng Y: Expression level of insulin-
like growth factor binding protein 5 mRNA is a prognostic
factor for breast cancer.  Cancer Sci 2007, 98:1592-1596.
19. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP,
Sahin AA: IGFBP2 and IGFBP5 overexpression correlates
with the lymph node metastasis in T1 breast carcinomas.
Breast J 2008, 14:261-267.
20. Butt AJ, Dickson KA, Jambazov S, Baxter RC: Enhancement of
tumor necrosis factor-alpha-induced growth inhibition by
insulin-like growth factor-binding protein-5 (IGFBP-5), but
not IGFBP-3 in human breast cancer cells.  Endocrinology 2005,
146:3113-3122.
21. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung
WK, Zhang W: Reactivation of insulin-like growth factor bind-
ing protein 2 expression in glioblastoma multiforme: a reve-
lation by parallel gene expression profiling.  Cancer Res 1999,
59:4228-4232.
22. Dundr M, Misteli T, Olson MO: The dynamics of postmitotic
reassembly of the nucleolus.  J Cell Biol 2000, 150:433-446.
23. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly MP: Differential
IGF- Independent Effects of Insulin-Like Growth Factor
Binding Proteins (1–6) on Apoptosis of Breast Epithelial
Cells.  J Cell Biochem 1999, 75:652-664.
24. Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM: Effects of
a non-IGF binding mutant of IGFBP-5 on cell death in human
breast cancer cells.  Biochem Biophys Res Commun 2002,
294:995-1000.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2009, 9:103 http://www.biomedcentral.com/1471-2407/9/103
Page 10 of 10
(page number not for citation purposes)
25. Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, et
al.: Prognostic significance of insulin-like growth factor bind-
ing protein (IGFBP)-4 and IGFBP-5 expression in breast can-
cer.  Jpn J Clin Oncol 2007, 37:575-582.
26. Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F, et al.:
Genome-wide gene expression profiles of breast cancer cells
purified with laser microbeam microdissection: identifica-
tion of genes associated with progression and metastasis.  Int
J Oncol 2004, 25:797-819.
27. Jurgeit A, Berlato C, Obrist P, Ploner C, Massoner P, Schmölzer J, et
al.: Insulin-like growth factor-binding protein-5 enters vesicu-
lar structures but not the nucleus.  Traffic 2007, 8:1815-1828.
28. Vogelstein B, Kinzler KW: Cancer genes and the pathways they
control.  Nat Med 2004, 10:789-799.
29. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53
in breast cancer: mutation and nuclear exclusion.  Proc Natl
Acad Sci USA 1992, 89:7262-7266.
30. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zam-
betti G: Cytoplasmic sequestration of wild-type p53 protein
impairs the G1 checkpoint after DNA damage.  Mol Cell Biol
1996, 16:1126-1137.
31. Moll UM, LaQuaglia M, Bénard J, Riou G: Wild-type p53 protein
undergoes cytoplasmic sequestration in undifferentiated
neuroblastomas but not in differentiated tumors.  Proc Natl
Acad Sci USA 1995, 92:4407-4411.
32. Sun XF, Carstensen JM, Zhang H, Stål O, Wingren S, Hatschek T,
Nordenskjöld B: Prognostic significance of cytoplasmic p53
oncoprotein in colorectal adenocarcinoma.  Lancet 1992,
340:1369-1373.
33. Fontoura BM, Atienza CA, Sorokina EA, Morimoto T, Carroll RB:
Cytoplasmic p53 polypeptide is associated with ribosomes.
Mol Cell Biol 1997, 17:3146-3154.
34. Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV,
Fojo T: p53 is associated with cellular microtubules and is
transported to the nucleus by dynein.  Nat Cell Biol 2000,
2:709-717.
35. Klotzsche O, Etzrodt D, Hohenberg H, Bohn W, Deppert W: Cyto-
plasmic retention of mutant tsp53 is dependent on an inter-
mediate filament protein (vimentin) scaffold.  Oncogene 1998,
16:3423-3434.
36. Nikolaev AY, Li M, Puskas N, Qin J, Gu W: Parc: a cytoplasmic
anchor for p53.  Cell 2003, 112:29-40.
37. Nikolaev AY, Gu W: PARC: a potential target for cancer ther-
apy.  Cell Cycle 2003, 2:169-171.
38. Kim KS, Seu YB, Baek SH, Kim MJ, Kim KJ, Kim JH, Kim JR: Induction
of cellular senescence by insulin-like growth factor binding
protein-5 through a p53-dependent mechanism.  Mol Biol Cell
2007, 18:4543-4552.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/103/pre
pub